论文部分内容阅读
目的通过检测56例恶性消化系统肿瘤患者血浆D-二聚体水平,以探讨恶性消化系统肿瘤患者凝血及纤溶状态变化与肿瘤发生、发展的关系。方法采用美国贝克曼ACL-7000检测仪,采用免疫比浊法测出样本含量(56例消化系统恶性肿瘤患者和20例正常对照组血浆D-二聚体含量)。结果前者显著高于后者(P<0.05),在肿瘤组中以肝癌最高,依次为胰腺癌、胃癌、食道癌,肝癌与食道癌相比有显著性差异(P<0.05),余各组间无显著性差异(P>0.05)。结论测定血浆D-二聚体含量可作为诊断消化系统肿瘤的实验室依据之一。
Objective To detect the level of plasma D-dimer in 56 patients with malignant digestive system tumors to investigate the relationship between coagulation and fibrinolytic status and tumorigenesis and development in patients with malignant digestive system tumors. Methods The Beckman ACL-7000 detector was used to detect the sample content (plasma D-dimer levels in 56 patients with digestive system malignancies and 20 normal controls) by immunoturbidimetry. Results The former was significantly higher than the latter (P <0.05), and the highest was liver cancer in tumor group, followed by pancreatic cancer, gastric cancer, esophageal cancer, liver cancer and esophageal cancer (P <0.05) There was no significant difference (P> 0.05). Conclusion The determination of plasma D-dimer content can be used as a laboratory basis for the diagnosis of digestive system tumors.